Navigation Links
Omeros Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference
Date:9/20/2013

SEATTLE, Sept. 20, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the NewsMakers in the Biotech Industry 2013 Conference in New York City next week.  The presentation is scheduled for Friday, September 27, 2013 at 2:00 p.m. EDT.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery® platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has six clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the pharmaceutical industry. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Contact:
Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
360.668.3701
jennifer@cwcomm.org


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
2. Omeros Reports Additional Positive Results from OMS824 Program
3. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
4. Omeros to Present at the Stifel Healthcare Conference 2013
5. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
6. Omeros Corporation Reports Second Quarter 2013 Financial Results
7. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
8. Omeros Submits New Drug Application to U.S. FDA for OMS302
9. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
10. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
11. Omeros Corporation Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
(Date:2/4/2016)... 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ... into a settlement agreement with the United States ... SEC,s investigation into possible violations of the Foreign ... the settlement agreement, SciClone has agreed to pay ... interest and a penalty.  This payment is in ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Identifying and Commercializing First-in-Class Innovation ... disorder associated with chronic inflammation of the airways ... of COPD symptoms make the disease one of ... cause of death in the world. COPD is ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... The Muscular Dystrophy Association and Sailormen ... the 14th annual “Appetite for a Cure” campaign on Feb. 1 to raise ... related diseases that severely limit strength and mobility. , Now through March ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled to ... the most effective tattoo removal today, Dr. Bentkover is the only doctor in Central ... the PicoSure has been approved by the Food and Drug Administration (FDA) as a ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... mobile kitchens, recently announced the debut of their latest mobile kitchen model, featuring ... provides organizations with modern, high-volume commercial kitchens for use anywhere in the U.S. ...
Breaking Medicine News(10 mins):